Indeed Snapshot

Track Adaptimmune Therapeutics reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 29th, 2022 12:00AM Open Adaptimmune Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 29th, 2022 11:17AM Aug 29th, 2022 11:17AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 28th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 28th, 2022 04:16AM Aug 28th, 2022 04:16AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 27th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 27th, 2022 03:36AM Aug 27th, 2022 03:36AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 25th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 25th, 2022 08:16AM Aug 25th, 2022 08:16AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 23rd, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 23rd, 2022 10:08AM Aug 23rd, 2022 10:08AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 21st, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 21st, 2022 11:52AM Aug 21st, 2022 11:52AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 20th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 20th, 2022 01:29PM Aug 20th, 2022 01:29PM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 19th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 19th, 2022 11:53AM Aug 19th, 2022 11:53AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 18th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 18th, 2022 03:36AM Aug 18th, 2022 03:36AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:adap https://www.indeed.com/cmp/adaptimmune Aug 17th, 2022 12:00AM Open Adaptimmune Pharmaceutical & Biotechnology Transforming cancer immunotherapy with affinity enhanced T-cell receptors Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. 3.60 8.00 8.00 3.60 3.90 3.10 3.10 3.90 Aug 17th, 2022 09:15AM Aug 17th, 2022 09:15AM Adaptimmune Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.